FRANKFURT (Reuters) – Glaxosmithkline (LON:) said that Moncef Slaoui has been dismissed as chairman of Galvani Bioelectronics, which is majority owned by GSK.
GSK said the termination of Slaoui’s contract was with immediate effect. Slaoui was not immediately available for comment.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment